Annual report pursuant to Section 13 and 15(d)

REGISTERED DIRECT OFFERING 2017 (Details Textual)

v3.8.0.1
REGISTERED DIRECT OFFERING 2017 (Details Textual) - USD ($)
1 Months Ended 12 Months Ended
Nov. 14, 2017
Mar. 03, 2017
Feb. 24, 2017
Feb. 20, 2017
Sep. 30, 2017
Sep. 30, 2016
Sep. 28, 2016
Sep. 30, 2013
Repayments of Notes Payable         $ 1,000,000 $ 0    
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)         $ (433,923) 192,128    
Registered Direct Offering 2017 [Member]                
Repayments of Notes Payable           $ 50,000,000    
Stock Issued During Period, Shares, New Issues       10,166,664        
Shares Issued, Price Per Share       $ 0.60        
Cash Price Per Each Common Stock Underlying Warrants     $ 0.18          
Allocation Of Remaining Proceeds To Common Stock And Additional Paid In Capital     2,991,012          
Payments of Stock Issuance Costs     112,000          
Stock Issued During Period, Value, New Issues     6,100,000          
Derivative Liability     2,996,110          
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) $ 433,923              
Massachusetts Life Sciences Center [Member]                
Repayments of Notes Payable   $ 830,000 $ 830,000          
Class of Warrant or Right, Exercise Price of Warrants or Rights               $ 0.27
Qualified Financing Minimum Net Proceeds             $ 5,000,000  
Common Stock [Member]                
Stock Issued During Period, Shares, New Issues     10,166,664          
Class of Warrant or Right, Exercise Price of Warrants or Rights       $ 0.75        
Series F Warrant [Member] | Registered Direct Offering 2017 [Member]                
Stock Issued During Period, Value, New Issues     $ 5,987,122          
Percentage of Class of Warrant Or Right Held       20.00%